Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Trade Setup for May 27: Nifty holds on to key levels as market moves from one expiry to another
The Nifty Bank was the key contributor in the Nifty exhibiting sluggish moves on expiry day, but unlike the Nifty, the banking index continued to trade in a broad range. Despite a 500-point fall from the day's high, the index managed to hold on to the 55,000 mark on a closing basis, something the bulls could take heart from. Tuesday's high of 55,536 will be the first level to watch on the upside.
Aarti Pharmalabs Q4 Results: Shares slide 6% as forex loss, one-offs impact earnings performance
Aarti Pharmalabs recognised fair value losses related to a target redemption forward contract entered into during FY25 for hedging anticipating US dollar export inflows. The total fair value impact recognised in FY26 stood at ₹29.7 crore.
Bharti, Vodafone Idea tower additions will take Indus Towers shares higher by 32%, CLSA says
With the company's high free cash flow, its dividend payouts should continue and its yields also have an upside, according to CLSA, who went on to add that at 6 times its Enterprise Value to EBITDA, the valuations of Indus Towers are cheap.
Poly Medicure shares slide 5% after Q4 net profit drops 28%; declares ₹3.5 dividend
The company’s board recommended a dividend of ₹3.5 per equity share of face value ₹5 each for FY26, subject to shareholders’ approval. Shares of Poly Medicure Ltd ended at ₹1,518.00, down by ₹80.75, or 5.05%, on the BSE.
Anupam Rasayan to acquire up to 43 pc stake in Bliss GVS Pharma for around Rs 1,369 cr
Specialty chemicals maker Anupam Rasayan India is set to acquire up to 43.3% of Bliss GVS Pharma for an estimated Rs 1,369.51 crore, with an open offer for an additional 26%. This strategic move aims to strengthen Anupam Rasayan's presence across the pharmaceutical value chain, from key starting materials to finished dosage formulations.
Anupam Rasayan enters formulations business with ₹1,369 cr Bliss GVS Pharma acquisition
Anupam Rasayan will acquire up to 74.2% stake in Bliss GVS Pharma, strengthening its presence across the pharmaceutical value chain and expanding its reach in regulated global markets.
Fortis Healthcare Q4 profit up 45% on lower exceptional losses, higher revenue
The board recommended a final dividend of ₹1 per equity share of face value ₹10 each for FY26. Shares of Fortis Healthcare Limited ended ₹5.40 lower at ₹961.90 on the NSE today, May 22.
Venus Remedies receives Saudi FDA approval for Plerixafor
Venus Remedies has received Marketing Authorization from the Saudi Food and Drug Authority (SFDA) for Plerixafor. This is the first Marketing Authorization Venus Remedies has secured for Plerixafor anywhere in the world. It is also a deliberate step in the company's move toward complex, higher-value specialty injectables in oncology and critical care, replacing reliance on commodity injectable volumes with diifferentiated therapies in regulated markets.
Apollo Hospitals rises 4% to hit 52-week high on Q4 show, dividend news
Apollo Hospitals Enterprise's board has recommended a final dividend of ₹10 per equity share (200 per cent) of face value of ₹5 per share for FY2025-26
Zerodha's Nithin Kamath warns of rising risks in booming MTF market
MTF allows investors to buy stocks by paying only a portion of the total value upfront, with brokers funding the remaining amount. This helps traders take larger positions with limited capital and can amplify gains in rising markets.
Sun Pharma Advanced Research Company raises Rs 150 cr via warrant issuance
Each of the Warrant, so allotted, is convertible into or exchangeable for one fully paid-up equity share of face value of Re 1/- of the Company in accordance with the provisions of SEBI ICDR Regulations.
Nifty could hit 27,000 once geopolitical tensions ease: Bajaj Finserv AMC CIO
Bajaj Finserv AMC CIO Nimesh Chandan projects 15% earnings growth for Nifty in FY28, with EPS rising to the ₹1,420–1,440 range, making valuations look attractive. He backs metals, construction, and cement as long-term plays on a global supply chain shift, holds gold and silver in the multi-asset portfolio, and flags El Niño and elevated US yields as key risks keeping Indian interest rates high in the near term.